Survey - ML-Air pollution & ARMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File Impact of Air Pollution on Allergic Rhinitis: Real-World Insights & Management Practices among HCPs”1. Approximately what proportion of your Allergic Rhinitis (AR) patients have symptoms that you associate with air pollution exposure? More than 75% of patients 50–75% of patients 25–50% of patients Less than 25% of patients2. Compared with 3–5 years ago, how has the incidence of pollutiontriggered AR changed in your practice? Increased by (more than 50%) Increased by 25–50% Slight increase (less than 25%) No noticeable change3. Which symptom is most commonly aggravated by air pollution in AR patients? Nasal congestion Sneezing Rhinorrhea Ocular symptoms4. Which patient group is most vulnerable to pollution-induced worsening of AR? Children Young working adults Elderly Patients with asthma or other respiratory comorbidities5. How often do you enquire about environmental or occupational pollution exposure while evaluating AR patients? Always Often Sometimes Rarely6. What do you consider the primary mechanism by which air pollution worsens Allergic Rhinitis? Enhanced airway inflammation Increased allergen sensitization Impaired nasal mucosal barrier Combination of all these mechanisms7. What is the biggest challenge in managing pollution-associated AR? Persistent nasal congestion Frequent symptom recurrence Poor patient adherence Continuous environmental exposure8. Despite treatment, how often do your patients continue to experience symptoms during periods of high pollution? Frequently Occasionally Rarely Almost never9. Which management strategy do you prioritize during periods of increased air pollution? Escalating pharmacotherapy Intranasal therapy optimization Environmental control measures Combination of pharmacological and preventive measures10. Which outcome best defines successful management of pollutionassociated AR? Complete symptom control Reduction in exacerbations Improved quality of life Reduced disease recurrence during pollution peaks11. In AR patients whose symptoms worsen with air pollution, which oral combination do you most commonly prefer? Montelukast + Levocetirizine Montelukast + Fexofenadine Montelukast + Bilastine Antihistamine monotherapy12. What is the primary reason for choosing a Montelukast-based combination in pollution-associated AR? Better control of nasal congestion Broader control of allergic inflammation Better symptom control in patients with respiratory comorbidities Reduced recurrence during prolonged pollution exposure I have read and agree to the Terms and Conditions .Submit Form